CEACAM5 and neoplasm: Up to date, there are only limited blood tumor biomarkers available, including alpha-fetoprotein (AFP), cancer antigen 19-9 (CA19-9), and carcinoembryonic antigen (CEA), whose sensitivities remain far from satisfactory.